COVID-19-associated venous thromboembolism: risk of recurrence and major bleeding

Background: Complications under anticoagulant treatment in patients with COVID-19-associated venous thromboembolism (VTE) have not been consistently reported.Objectives: This study aimed to compare the 90-day rates of VTE recurrences and major bleeding in patients with COVID-19-associated VTE versus...

Descripción completa

Detalles Bibliográficos
Autores: Demelo-Rodriguez, P, Alonso-Beato, R, Jara-Palomares, L, Galeano-Valle, F, Bura-Riviere, A, Visonà, A, Francisco, I, Vidal, G, López-Ruiz, A, Monreal, M
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Institut d'Investigació i Innovació Parc Taulí (I3PT)
Repositorio:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
OAI Identifier:oai:i3pt.fundanetsuite.com:p4194
Acceso en línea:https://i3pt.portalinvestigacion.com/publicaciones/4194
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85173189512&doi=10.1016%2fj.rpth.2023.102206&partnerID=40&md5=87c80c6e398262a6408caf5839f34d90
Access Level:acceso abierto
Palabra clave:anticoagulants
COVID-19
hemorrhage
pulmonary embolism
venous thromboembolism
id ES_d4e16ae3c3d915454f73edccbdcf3fce
oai_identifier_str oai:i3pt.fundanetsuite.com:p4194
network_acronym_str ES
network_name_str España
repository_id_str
spelling COVID-19-associated venous thromboembolism: risk of recurrence and major bleedingDemelo-Rodriguez, PAlonso-Beato, RJara-Palomares, LGaleano-Valle, FBura-Riviere, AVisonà, AFrancisco, IVidal, GLópez-Ruiz, AMonreal, ManticoagulantsCOVID-19hemorrhagepulmonary embolismvenous thromboembolismBackground: Complications under anticoagulant treatment in patients with COVID-19-associated venous thromboembolism (VTE) have not been consistently reported.Objectives: This study aimed to compare the 90-day rates of VTE recurrences and major bleeding in patients with COVID-19-associated VTE versus those with VTE without COVID-19.Methods: We used the RIETE registry to compare the 3-month outcomes in patients with COVID-19-associated VTE versus those with VTE without COVID-19.Results: The study included 1,747 patients with COVID-19-associated VTE and 8,711 with VTE without COVID-19. Patients with COVID-19-associated VTE were more likely to be hospitalized at baseline and to present with pulmonary embolism. During the first 90 days, 123 patients (1.17%) developed VTE recurrences, and 266 (2.54%) experienced major bleeding. Patients with COVID-19-associated VTE had a similar rate of VTE recurrences (0.9% vs 1.2%) but a higher rate of major bleeding (4.6% vs 2.1%; P < .001) than those without COVID-19. Multivariable analysis adjusted for competing risks showed that patients with COVID-19-associated VTE had an increased risk of major bleeding (subhazard ratio, 1.395; 95% confidence interval, 1.037-1.877). The 30-day mortality after major bleeding was 26.3% in patients with COVID-19-associated VTE and 17.7% in those without COVID-19.Conclusion: Patients with COVID-19-associated VTE had a 5-fold higher rate of major bleeding than VTE recurrences during the first 90 days of anticoagulation. In VTE patients without COVID-19, both rates were similar. These findings highlight the importance of carefully monitoring and optimizing anticoagulation in these patients.ELSEVIER2023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://i3pt.portalinvestigacion.com/publicaciones/4194https://www.scopus.com/inward/record.uri?eid=2-s2.0-85173189512&doi=10.1016%2fj.rpth.2023.102206&partnerID=40&md5=87c80c6e398262a6408caf5839f34d90Research and Practice in Thrombosis and HaemostasisISSN: 24750379reponame:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulíinstname:Institut d'Investigació i Innovació Parc Taulí (I3PT)Inglésinfo:eu-repo/semantics/openAccessoai:i3pt.fundanetsuite.com:p41942026-06-21T15:30:37Z
dc.title.none.fl_str_mv COVID-19-associated venous thromboembolism: risk of recurrence and major bleeding
title COVID-19-associated venous thromboembolism: risk of recurrence and major bleeding
spellingShingle COVID-19-associated venous thromboembolism: risk of recurrence and major bleeding
Demelo-Rodriguez, P
anticoagulants
COVID-19
hemorrhage
pulmonary embolism
venous thromboembolism
title_short COVID-19-associated venous thromboembolism: risk of recurrence and major bleeding
title_full COVID-19-associated venous thromboembolism: risk of recurrence and major bleeding
title_fullStr COVID-19-associated venous thromboembolism: risk of recurrence and major bleeding
title_full_unstemmed COVID-19-associated venous thromboembolism: risk of recurrence and major bleeding
title_sort COVID-19-associated venous thromboembolism: risk of recurrence and major bleeding
dc.creator.none.fl_str_mv Demelo-Rodriguez, P
Alonso-Beato, R
Jara-Palomares, L
Galeano-Valle, F
Bura-Riviere, A
Visonà, A
Francisco, I
Vidal, G
López-Ruiz, A
Monreal, M
author Demelo-Rodriguez, P
author_facet Demelo-Rodriguez, P
Alonso-Beato, R
Jara-Palomares, L
Galeano-Valle, F
Bura-Riviere, A
Visonà, A
Francisco, I
Vidal, G
López-Ruiz, A
Monreal, M
author_role author
author2 Alonso-Beato, R
Jara-Palomares, L
Galeano-Valle, F
Bura-Riviere, A
Visonà, A
Francisco, I
Vidal, G
López-Ruiz, A
Monreal, M
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv anticoagulants
COVID-19
hemorrhage
pulmonary embolism
venous thromboembolism
topic anticoagulants
COVID-19
hemorrhage
pulmonary embolism
venous thromboembolism
description Background: Complications under anticoagulant treatment in patients with COVID-19-associated venous thromboembolism (VTE) have not been consistently reported.Objectives: This study aimed to compare the 90-day rates of VTE recurrences and major bleeding in patients with COVID-19-associated VTE versus those with VTE without COVID-19.Methods: We used the RIETE registry to compare the 3-month outcomes in patients with COVID-19-associated VTE versus those with VTE without COVID-19.Results: The study included 1,747 patients with COVID-19-associated VTE and 8,711 with VTE without COVID-19. Patients with COVID-19-associated VTE were more likely to be hospitalized at baseline and to present with pulmonary embolism. During the first 90 days, 123 patients (1.17%) developed VTE recurrences, and 266 (2.54%) experienced major bleeding. Patients with COVID-19-associated VTE had a similar rate of VTE recurrences (0.9% vs 1.2%) but a higher rate of major bleeding (4.6% vs 2.1%; P < .001) than those without COVID-19. Multivariable analysis adjusted for competing risks showed that patients with COVID-19-associated VTE had an increased risk of major bleeding (subhazard ratio, 1.395; 95% confidence interval, 1.037-1.877). The 30-day mortality after major bleeding was 26.3% in patients with COVID-19-associated VTE and 17.7% in those without COVID-19.Conclusion: Patients with COVID-19-associated VTE had a 5-fold higher rate of major bleeding than VTE recurrences during the first 90 days of anticoagulation. In VTE patients without COVID-19, both rates were similar. These findings highlight the importance of carefully monitoring and optimizing anticoagulation in these patients.
publishDate 2023
dc.date.none.fl_str_mv 2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://i3pt.portalinvestigacion.com/publicaciones/4194
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85173189512&doi=10.1016%2fj.rpth.2023.102206&partnerID=40&md5=87c80c6e398262a6408caf5839f34d90
url https://i3pt.portalinvestigacion.com/publicaciones/4194
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85173189512&doi=10.1016%2fj.rpth.2023.102206&partnerID=40&md5=87c80c6e398262a6408caf5839f34d90
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv ELSEVIER
publisher.none.fl_str_mv ELSEVIER
dc.source.none.fl_str_mv Research and Practice in Thrombosis and Haemostasis
ISSN: 24750379
reponame:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
instname:Institut d'Investigació i Innovació Parc Taulí (I3PT)
instname_str Institut d'Investigació i Innovació Parc Taulí (I3PT)
reponame_str r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
collection r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869420585230008320
score 15.811543

Similares en LA Referencia